SV Life Sciences
ActiveBoston, MALast fund filed August 2021Biotechnology, Healthcare, Pharmaceuticals
Boston, MALast fund filed August 2021Biotechnology, Healthcare, Pharmaceuticals
0 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| SV Life Sciences Fund IV CF, L.P. | August 2021 | $421.4M | $421.4M | 44 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. Form D carries no per-investor amount, so a firm’s own cheque is not recoverable here.
8 partners are named across this firm’s filings, 0 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats, 24mo |
|---|---|---|---|
| Michael RossOn the current fund | Selective | None listed | 3 |
| Paul LaVioletteOn the current fund | Slowing | None listed | 1 |
| Eugene HillOn the current fund | Quiet | None listed | 0 |
| Greg MaddenOn the current fund | Quiet | None listed | 0 |
| Houman AshrafianOn the current fund | Quiet | None listed | 0 |
| Kate BinghamOn the current fund | Quiet | None listed | 0 |
| Michael BalmuthOn the current fund | Quiet | None listed | 0 |
| Thomas FlynnOn the current fund | Quiet | None listed | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. On a firm it is the total across its partners, so an active firm may be four partners taking one seat each rather than one person moving fast. It undercounts partners who invest without taking a board seat, and Form D lags a closing by weeks — so Quiet means the paperwork is quiet, not the person.